Regional enteritis involving the duodenum: report of case.

S. E. Roberts,W. J. Martin,O. Beahrs

Abstract:

What problem does this paper attempt to address?

Biolimus-coated Versus Paclitaxel-Coated Balloons for Coronary In-Stent Restenosis (BIO ASCEND ISR): a Randomised, Non-Inferiority Trial.

Yundai Chen,Lei Gao,Qin,Jun Zhang,Shaobin Jia,Mingxing Wu,Yong He,Guosheng Fu,Jinghua Liu,Hui Chen,Qian Tong,Zaixin Yu,Jian An,Chunguang Qiu,Biao Xu,Yu Cao,Changqian Wang,Genshan Ma

DOI: https://doi.org/10.4244/eij-d-24-00295

2024-01-01

EuroIntervention

Abstract:BACKGROUND: The treatment of in-stent restenosis (ISR) after drug-eluting stent (DES) implantation remains challenging in current clinical practice. AIMS: The study was conducted to investigate a novel biolimus-coated balloon (BCB) for the treatment of coronary DES-ISR compared with the best-investigated paclitaxel-coated balloon (PCB). METHODS: This was a prospective, multicentre, randomised, non-inferiority trial comparing a novel BCB with a clinically proven PCB for coronary DES-ISR. The primary endpoint was in-segment late lumen loss (LLL) at 9 months assessed by an independent core laboratory. Baseline and follow-up optical coherence tomography were performed in a prespecified subgroup of patients. RESULTS: A total of 280 patients at 17 centres were randomised to treatment with a BCB (n=140) versus a PCB (n=140). At 9 months, LLL in the BCB group was 0.23 +/- 0.37 mm compared to 0.25 +/- 0.35 mm in the PCB group; the mean difference between the groups was -0.02 (95% confidence interval [CI]: -0.12 to 0.07) mm; p-value for non-inferiority<0.0001. Similar clinical outcomes were also observed for both groups at 12 months. In the optical coherence tomography substudy, the neointimal area at 9 months was 2.32 +/- 1.04 mm (2) in the BCB group compared to 2.37 +/- 0.93 mm (2) in the PCB group; the mean difference between the groups was -0.09 (95% CI: -0.94 to 0.76) mm (2) ; p=non-significant. CONCLUSIONS: This head-to-head comparison of a novel BCB shows similar angiographic outcomes in the treatment of coronary DES-ISR compared with a clinically proven PCB.
A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial

Gao Run-Lin,Xu Bo,Alexandra J. Lansky,Yang Yue-Jin,Ma Chang-Sheng,Han Ya-Ling,Chen Shao-Liang,Li Hui,Zhang Rui-Yan,Fu Guo-Sheng,Yuan Zu-Yi,Jiang Hong,Huo Yong,Li Wei,Zhang Yao-Jun,Martin B. Leon,null null

DOI: https://doi.org/10.4244/EIJV9I1A12

2013-01-01

EuroIntervention

Abstract:Aims: The study sought to evaluate the safety and efficacy of FIREHAWK, a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent (SES) for treating patients with single de novo coronary lesions compared with the durable polymer everolimus-eluting stent (EES) XIENCE V. Methods and results: A total of 458 patients with single de novo native coronary lesions <= 24 mm in length and a coronary artery >= 2.25 to <= 4.0 mm in diameter were enrolled in the TARGET I study, a prospective, randomised, non-inferiority trial. The primary endpoint was in-stent late lumen loss (LLL) at nine-month follow-up. The secondary endpoint, target lesion failure (TLF), was defined as the composite of cardiac death, target vessel myocardial infarction (TVMI), or ischaemia-driven target lesion revascularisation (iTLR). Patients were centrally randomised to treatment with either biodegradable polymer SES (n=227) or durable polymer EES (n=231). The nine-month in-stent LLL of the biodegradable polymer SES was comparable to the EES group (0.13 +/- 0.24 mm vs. 0.13 +/- 0.18 mm, p=0.94; difference and 95% confidence interval 0.00 [-0.04, 0.04] mm; p for non-inferiority <0.0001). Cardiac death (0.4% vs. 0.0%), TVMI (1.3% vs. 1.7%), iTLR (0.4% vs. 0.4%) and TLF (2.2% vs. 2.2%) were similar between the biodegradable polymer SES and durable polymer EES groups at 12-month follow-up (all p>0.05). No definite/probable stent thrombosis was observed in both of these groups. Conclusions: In the multicentre TARGET I trial, the novel abluminal groove-filled biodegradable polymer SES FIREHAWK was non-inferior to the durable polymer EES XIENCE V with respect to the primary endpoint of in-stent LLL at nine months for treating patients with single de novo coronary lesions. The incidences of clinical endpoints were low in both of the stents at 12-month follow-up.
Thinner-Strut Sirolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents in Patients with Coronary Artery Disease: FUTURE-II Trial

Lei Song,Bo Xu,Yundai Chen,Yujie Zhou,Shaobin Jia,Zhixiong Zhong,Xi Su,Yitong Ma,Qi Zhang,Jian Liu,Yang Wang,Changdong Guan,Ming Zheng,Shubin Qiao,Runlin Gao,Future-Ii Trial Investigators

DOI: https://doi.org/10.1016/J.JCIN.2021.04.048

2021-01-01

Abstract:ABSTRACT Objectives The present study sought to evaluate the safety and efficacy of thinner-strut Firesorb (100/125μm) sirolimus-eluting bioresorbable scaffolds (BRS) versus cobalt-chromium everolimus-eluting stents (CoCr-EES) in patients with coronary artery disease. Background First-generation thicker-strut BRS were associated with unexpected device-related adverse outcomes at long-term follow-up. Methods Eligible patients with 1 or 2 de novo noncomplex coronary lesions were randomized to Firesorb-BRS group or CoCr-EES group in a 1:1 ratio. The primary endpoint was 1-year angiographic in-segment late loss (LL) powered for noninferiority testing. The key secondary endpoint was 1-year proportion of covered struts assessed by optical coherence tomography (OCT) powered for noninferiority and subsequent superiority testing. Results A total of 433 participants from 28 Chinese centers were randomized to Firesorb-BRS group (n=215) or CoCr-EES group (n=218). Patient-level 1-year in-segment LL was 0.17±0.27 mm in the Firesorb-BRS group and 0.18±0.37 mm in the CoCr-EES group (difference, -0.01 mm; 95% confidence interval [CI], -0.07 to 0.06; pnoninferiority Conclusions The thinner-strut Firesorb BRS was noninferior to CoCr-EES for the primary endpoint of 1-year angiographic in-segment LL and the key secondary endpoint of 1-year proportion of covered struts by OCT.
A randomized comparison of healing response of the BuMA Supreme stent and Xience stent at one- and two-month follow-up: PIONEER-II OCT randomized controlled trial.

Taku Asano,Qinhua Jin,Yuki Katagiri,Norihiro Kogame,Kuniaki Takahashi,Chun-Chin Chang,Ply Chichareon,ChangQian Wang,Bei Shi,Xi Su,Guosheng Fu,YanQing Wu,XuChen Zhou,Zuyi Yuan,Joanna J Wykrzykowska,Jan J Piek,Patrick W Serruys,Yoshinobu Onuma,YunDai Chen

DOI: https://doi.org/10.4244/EIJ-D-18-00461

2018-01-01

EuroIntervention

Abstract:Aims: The aim of this study was to compare the strut coverage of the XIENCE stent with that of the BuMA Supreme sirolimus-eluting cobalt-chromium stent, which has a shorter drug elution, on optical coherence tomography (OCT) one or two months after implantation. Methods and results: The PIONEER-II OCT trial was a multicentre, two-arm randomised trial, which comprised two cohorts: cohort-1 underwent an OCT imaging one month after coronary intervention (BuMA: 16 patients with 18 lesions, XIENCE: 15 patients with 17 lesions), whereas cohort-2 underwent OCT at two months (BuMA: 21 patients with 21 lesions, XIENCE: 23 patients with 28 lesions). The primary hypotheses were non-inferiority of the BuMA stent to the XIENCE stent in percent strut coverage at one month (cohort-1) or two months (cohort-2). In cohort-1, the BuMA stent was non-inferior to the XIENCE stent in terms of the strut coverage (83.8 +/- 10.4% for BuMA vs. 73.0 +/- 17.5% for XIENCE, p(for noninferiority) <0.001), and was also significantly higher than the XIENCE (p(for superiority) 0.037). In cohort-2, the BuMA stent was non-inferior to the XIENCE stent in OCT strut coverage (80.3 +/- 18.3% vs. 73.3 +/- 21.3%, p(for noninferiority) 0.006, p(for superiority) 0.24). Healing scores showed better healing in the BuMA stent in cohort-1 (32.36 +/- 21.59 vs. 54.88 +/- 34.65, p=0.027), whereas there was comparable healing between the BuMA and XIENCE stents in cohort-2 (39.86 +/- 37.77 vs. 53.75 +/- 42.84, p=0.25). Conclusions: The BuMA Supreme had a faster coverage than the XIENCE at one month, presumably due to faster and shorter sirolimus elution. The difference in tissue coverage became less evident at two months.
Long-Term Efficacy, Safety and Biocompatibility of a Novel Sirolimus Eluting Iron Bioresorbable Scaffold in a Porcine Model

Ya-Nan Gao,Hong-Tao Yang,Zi-Feng Qiu,Feng Qi,Qian-Hong Lu,Jian-Feng Zheng,Zi-Wei Xi,Xin Wang,Li,Gui Zhang,De-Yuan Zhang,Yu-Die Lu,Hai-Ping Qi,Hong Qiu,Run-Lin Gao,Yu-Feng Zheng

DOI: https://doi.org/10.1016/j.bioactmat.2024.05.027

IF: 18.9

2024-01-01

Bioactive Materials

Abstract:Iron is considered as an attractive alternative material for bioresorbable scaffolds (BRS). The sirolimus eluting iron bioresorbable scaffold (IBS), developed by Biotyx Medical (Shenzhen, China), is the only iron-based BRS with an ultrathin-wall design. The study aims to investigate the long-term efficacy, safety, biocompatibility, and lumen changes during the biodegradation process of the IBS in a porcine model. A total of 90 IBSs and 70 cobalt-chromium everolimus eluting stents (EES) were randomly implanted into nonatherosclerotic coronary artery of healthy mini swine. The multimodality assessments including coronary angiography, optical coherence tomography, micro-computed tomography, magnetic resonance imaging, real-time polymerase chain reaction (PCR), and histopathological evaluations, were performed at different time points. There was no statistical difference in area stenosis between IBS group and EES group at 6 months, 1year, 2 years and 5 years. Although the scaffolded vessels narrowed at 9 months, expansive remodeling with increased mean lumen area was found at 3 and 5 years. The IBS struts remained intact at 6 months, and the corrosion was detectable at 9 months. At 5 years, the iron struts were completely degraded and absorbed in situ, without in-scaffold restenosis or thrombosis, lumen collapse, aneurysm formation, and chronic inflammation. No local or systemic toxicity and abnormal histopathologic manifestation were found in all experiments. Results from real-time PCR indicated that no sign of iron overload was reported in scaffolded segments. Therefore, the IBS shows comparable efficacy, safety, and biocompatibility with EES, and late lumen enlargement is considered as a unique feature in the IBS-implanted vessels.
GW29-e2015 Primary Endpoint Outcomes of A Prospective, Single-Blinded, Multi-Center, Randomized, Controlled, Clinical Trial on the Efficacy and Safety of Sirolimus-Eluting Stent (mistent® System) Compared to TIVOLI in the Treatment of Patients with Coronary Heart Disease

Yaling Han,Zhiyong Wang,Hanjun Pei,Li Zhang,Yuejin Yang,Bo Xu,Yang Zheng,Zheng Zhang,Xinqun Hu,Ziwen Ren,Feng Zheng,Zhiming Yang,Renqiang Yang,Changqian Wang,Yuexi Wang,Guosheng Fu,Yu Cao,Zuyi Yuan,Bin Wang,Quanmin Jing

DOI: https://doi.org/10.1016/j.jacc.2018.08.2176

IF: 24

2018-01-01

Journal of the American College of Cardiology

Abstract:To date there have been no randomized clinical trials comparing the outcomes of two bioabsorbable polymer coated coronary stents. Micell Technologies has developed the MiStent Sirolimus Eluting Absorbable Polymer Coronary Stent System (“MiStent”) consisting of a cobalt-chromium stent platform
In vivo degradation and endothelialization of an iron bioresorbable scaffold

Wenjiao Lin,Hongjie Zhang,Wanqian Zhang,Haiping Qi,Gui Zhang,Jie Qian,Xin Li,Li Qin,Haifeng Li,Xiang Wang,Hong Qiu,Xiaoli Shi,Wei Zheng,Deyuan Zhang,Runlin Gao,Jiandong Ding

DOI: https://doi.org/10.1016/j.bioactmat.2020.09.020

IF: 18.9

2021-04-01

Bioactive Materials

Abstract:Detection of in vivo biodegradation is critical for development of next-generation medical devices such as bioresorbable stents or scaffolds (BRSs). In particular, it is urgent to establish a nondestructive approach to examine in vivo degradation of a new-generation coronary stent for interventional treatment based on mammal experiments; otherwise it is not available to semi-quantitatively monitor biodegradation in any clinical trial. Herein, we put forward a semi-quantitative approach to measure degradation of a sirolimus-eluting iron bioresorbable scaffold (IBS) based on optical coherence tomography (OCT) images; this approach was confirmed to be consistent with the present weight-loss measurements, which is, however, a destructive approach. The IBS was fabricated by a metal-polymer composite technique with a polylactide coating on an iron stent. The efficacy as a coronary stent of this new bioresorbable scaffold was compared with that of a permanent metal stent with the name of trade mark Xience, which has been widely used in clinic. The endothelial coverage on IBS was found to be greater than on Xience after implantation in a rabbit model; and our well-designed ultrathin stent exhibited less individual variation. We further examined degradation of the IBSs in both minipig coronary artery and rabbit abdominal aorta models. The present result indicated much faster iron degradation of IBS in the rabbit model than in the porcine model. The semi-quantitative approach to detect biodegradation of IBS and the finding of the species difference might be stimulating for fundamental investigation of biodegradable implants and clinical translation of the next-generation coronary stents.

engineering, biomedical,materials science, biomaterials
Design and Rationale of Targeted Therapy With a Sirolimus-Eluting, Biodegradable Polymer Coronary Stent in Chronic Total Occlusions (TARGET CTO): A Multicenter, Open-Label, Randomized Noninferiority Trial.

Yaling Han,Geng Wang,Yi Li,Ming Zheng,Ruifen Cao,Ruiyan Zhang,Shaoliang Chen,Jian'an Wang,Yitong Ma,Zhiqi Sun,Xueqi Li,Xi Su,Wen Lu,Yawei Xu,Ernest Spitzer,Xue Li,Fucheng Sun

DOI: https://doi.org/10.1016/j.jscai.2022.100511

2022-01-01

Journal of the Society for Cardiovascular Angiography & Interventions

Abstract:Background:Treatment of chronic total occlusions (CTOs) is referred to as the last frontier of percutaneous coronary interventions and is currently performed in 10% to 20% of procedures. Improved outcomes with newer generation drug-eluting stents require further research. Methods:The TARGET CTO trial (NCT03040934) is a prospective, multicenter, randomized, noninferiority trial that plans to randomize 196 subjects (1:1) to either a newer-generation sirolimus target-eluting stent or an everolimus-eluting stent. Patients are candidates if they present with at least 1 CTO lesion in a native coronary artery with a diameter of ≥2.50 mm to ≤4.00 mm and a length of <100 mm. In addition, 44 subjects will participate in an optical coherence tomography (OCT) substudy. Clinical follow-up is planned up to 5 years after stent implantation. Angiographic follow-up is planned at 12 months, whereas OCT will be obtained after the procedure, at 3 and 12 months. The primary end point is in-stent late lumen loss by quantitative coronary angiography at 12 months. The key secondary end point is neointimal thickness by OCT at 3 months. Imaging end points are assessed by an independent core lab. Clinical end points are adjudicated by an independent clinical events committee. Conclusion:The TARGET CTO trial compares a sirolimus target-eluting stent with an everolimus-eluting stent for management of CTOs according to contemporary interventional practices. The primary angiographic end points will be reported at 12 months and clinical follow-up will continue for up to 5 years.
Twelve-month Angiographic and Clinical Outcomes of the XINSORB Bioresorbable Sirolimus-Eluting Scaffold and a Metallic Stent in Patients with Coronary Artery Disease

Yizhe Wu,Li Shen,Jiasheng Yin,Jiahui Chen,Juying Qian,Lei Ge,Junbo Ge

DOI: https://doi.org/10.1016/j.ijcard.2019.06.053

IF: 4.039

2019-01-01

International Journal of Cardiology

Abstract:Background: Recent studies showed bioresorbable scaffold (BRS) increased risks of late target lesion failure (TLF) and thrombosis. XINSORB scaffold is a poly-L-lactic acid based BRS. Methods: The study included randomization and registry parts. Eligible patients with one or two de novo lesions were randomly 1:1 assigned to XINSORB scaffold and sirolimus-eluting stent (SES) in randomization part. These patients were clinically and angiographically assessed. In registry part, patients were treated with XINSORB scaffold only and were clinically assessed. The primary endpoint was in-segment late luminal loss (LLL) at 12-month in randomization part. The secondary endpoint was 12-month TLF in all XINSORB-treated patients. Results: Total 395 and 798 patients were enrolled in randomization and registry part, respectively. Device success was 98.0% (1069/1091) in all XINSORB-treated and 100% (221/221) in SES-treated lesions. The primary endpoint of in-segment LLL at 12-month was 0.19 +/- 0.32 mm in XINSORB and 0.31 +/- 0.41 mm in SES (P=0.003), which met the noninferior margin of 0.195 mm (95% CI: -0.20, -0.04, P << 0.0001). No difference was found in TLF between two devices. In all XINSORB-treated patients, 12-month TLF was 0.8% (8/998), which also met the noninferior margin of 9.0% (95% CI: 0.3%, 1.4%, P << 0.0001). Only one device thrombosis was recorded in all XINSORB-treated patients while none in SES. Conclusions: In the multicenter clinical trial, XINSORB BRS was noninferior to sirolimus-eluting stent for the primary endpoint of in-segment LLL at 12-month in patients with simple and moderate complex de novo coronary lesions. TLF at 12-month was low and comparable. (C) 2019 Published by Elsevier B.V.
Mid-to-long term clinical outcomes with everolimus-eluting bioresorbable vascular scaffold versus everolimus-eluting metallic stent in coronary artery diseases: a meta-analysis of 7321 patients

Xian-peng WU,Yi LU,Ting-ting FU,Xin-yang HU

DOI: https://doi.org/10.13191/j.chj.2018.0075

2018-01-01

Abstract:AIM To compare the mid-to-long term clinical outcomes between everolimus-eluting bioresorbable vascular scaffolds (BVS) and everolimus-eluting metallic stent (EES) in coronary artery diseases.METHODS The present investigation systematically searched electronic databases and abstracts or presentations from the latest international cardiovascular conferences up to January 8th 2018.RESULTS In total,11 studies with 7321 patients were enrolled,including 7 randomized controlled trials and 4 propensity score-matched designs.Pooled analysis revealed that the patients undergoing BVS implantation had a higher rate of definite or probable stent/scaffold thrombosis (ST) (odds ratio (OR) =3.08,95％confidence interval (CI):2.04 to 4.66,P ＜ 0.01),which was mainly attributed to the higher risks of early ST (OR =2.26,95％CI:1.26 to4.03,P=0.006) and very late ST (OR =4.46,95％CI:2.01 to 9.89,P＜0.01).Also,targetlesion failure (TLF) was more frequent in BVS (OR =1.34,95％ CI:1.11 to 1.60,P =0.002),which was related to the higher rates of target vessel myocardial infarction (OR =1.7 1,95％ CI:1.31 to 2.23,P ＜0.01) and ischemia driventarget lesion revascularization (OR =1.51,95％ CI:1.15 to 2.00,P =0.004) accompanied with BVS implantation.Myocardial infarction increased in BVS compared with EES (OR =1.52,95％ CI:1.22 to 1.90,P ＜0.01),but there were no significant differences in patient-oriented composite endpoint,all death,and all revascularization between BVS and EES.CONCLUSION Our meta-analysis demonstrated that compared with EES,BVS is associated with compromised clinical outcomes.Additional clinical outcomes of long-term large-scale clinical trials are warranted to further evaluate the use of BVS.
Three-year Clinical Outcomes of a Sirolimus-Eluting Bioresorbable Scaffold (XINSORB) and a Metallic Stent to Treat Coronary Artery Stenosis.

Yizhe Wu,Zhifeng Yao,Jiasheng Yin,Jiahui Chen,Juying Qian,Li Shen,Lei Ge,Junbo Ge

DOI: https://doi.org/10.21037/atm-20-6739

IF: 3.616

2020-01-01

Annals of Translational Medicine

Abstract:BACKGROUND:Recent studies have shown increased risks of late target lesion failure (TLF) and thrombosis using a bioresorbable scaffold (BRS). However, the results of the ABSORB China study offered a different means of understanding the long-term performance of BRSs. We tested the 3-year clinical outcome of the XINSORB BRS in a multicenter, randomized controlled clinical trial (ChiCTR1800014966).METHODS:Eligible patients with one or two de novo coronary lesions were randomly assigned 1:1 to be treated with XINSORB scaffolds and metallic sirolimus-eluting stents (SESs). The clinical endpoints include TLF [cardiac death, target vessel-related myocardial infarction (TV-MI), or ischemia-driven target lesion revascularization (ID-TLR)], its components, and devised thrombosis.RESULTS:Three hundred ninety-five patients were enrolled and randomized to the XINSORB (N=200) and SES (N=195) arms. The clinical 3-year follow-up included 95.5% of the XINSORB-treated patients and 92.8% of the SES-treated patients. Dual antiplatelet therapy was at 59.0% of the XINSORB-treated and 52.8% of the SES-treated patients (P=0.34). There were no significant differences in the clinical outcomes between the XINSORB and SES arms, including in TLF (4.0% vs. 6.2%, P=0.29), cardiac death (1.0% vs. 0%, P=NA), TV-MI (1.0% vs. 0%, P=NA), and ID-TLR (3.5% vs. 6.2%, P=0.19). The rate of confirmed/probable device thrombosis in the XINSORB-treated patients was only 1.0% (2/200).CONCLUSIONS:In this XINSORB randomized clinical trial, the XINSORB scaffolds and SESs showed similar efficacy and safety up to the 3-year follow-up. The rates of TLF and device thrombosis were low and comparable between the two arms.
Sirolimus-eluting Cobalt Alloyed Stents in Treating Patients with Coronary Artery Disease: Six-Month Angiographic and One-Year Clinical Follow-Up Result A Prospective, Historically Controlled, Multi-Center Clinical Study

Zhang Qi,Xu Bo,Yang Yue-jin,Zhang Rui-yan,Li Jian-ping,Qiao Shu-bin,Zhang Jian-sheng,Hu Jian,Qin Xue-wen,Hong Tao,Chen Ji-lin,Huo Yong,Shen Wei-feng,Gao Run-lin

DOI: https://doi.org/10.1097/00029330-200704010-00002

2007-01-01

Abstract:Background The emergence of drug-eluting stents (DES) has dramatically reduced the incidence of in-stent restenosis. This study was conducted to evaluate the safety and efficacy of sirolimus-eluting cobalt-chrome stents (Firebird 2) for treating patients with coronary artery disease.Methods Sixty-seven patients with de novo or non-stented restenostic coronary lesions were chosen to receive the Firebird 2 stent as the final treatment (Firebird 2 group). Another 49 consecutive patients were implanted with bare cobalt alloyed stents (Driver, Medtronic) within the previous six months and served as historical controls (control group). Baseline clinical characteristics, angiographic features, procedural results, 30-day, 6-month and 12-month clinical follow-up regarding the occurrence of major adverse cardiac events (MACE), as well as the primary endpoint of late lumen loss at 6-month angiographic follow-up were compared between the two groups.Results The demographic characteristics were similar between the two groups despite more patients in the Firebird 2 group who underwent previous percutaneous coronary intervention (22.4% vs 8.2%, P=0.0418) and who had diabetes mellitus (29.9% vs 12.2%, P=0.0253). In the Firebird 2 group, the mean diameter of the reference vessel was smaller ((2.79 +/- 0.46) mm vs (2.98 +/- 0.49) mm, P=0.0175) and more stents were implanted for each lesion (1.28 +/- 0.52 vs 1.10 +/- 0.30, P=0.0060). Other angiographic, procedural results and the device success rate were similar between the two groups. The MACE rate at 30-day and 3-month was the same, but significantly fewer MACE occurred in the Firebird 2 group at 6- and 12-month follow-up (1.5% vs 12.2% at 6 month, P=0.0168; 1.5% vs 26.5% at 12 month, P < 0.0001). The primary endpoint of late lumen loss at 6-month angiographic follow-up was significantly reduced in the Firebird 2 group (in-stent: (0.05 +/- 0.09) mm vs (0.98 +/- 0.61) mm; in-segment: (0.05 +/- 0.18) mm vs (0.72 +/- 0.59) mm; P < 0.0001) than the control group. One patient in the Firebird 2 group had in-segment restenosis (1.3%) while the rate in the control group (38.1 %) was significantly higher, P < 0.0001. Intravascular ultrasound examination was performed in 70.1 % of patients in the Firebird 2 group and revealed that the percentage of volumetric obstruction was (1.26 +/- 1.05) %. No stent thrombosis was observed in either group at 12-month follow-up.Conclusion The Firebird 2 sirolimus-eluting cobalt alloyed stent is safe and feasible in treating patients with coronary artery disease.
Regarding ‘efficacy and safety of a new surgical method to treat malignant glaucoma in pseudophakia’

W. Morgan

DOI: https://doi.org/10.1038/eye.2014.187

IF: 4.4563

2014-08-08

Eye

Abstract:
Bioresorbable Vascular Scaffolds Versus Metallic Stents in Patients with Coronary Artery Disease: ABSORB China Trial.

Runlin Gao,Yuejin Yang,Yaling Han,Yong Huo,Jiyan Chen,Bo Yu,Xi Su,Lang Li,Hai-Chien Kuo,Shih-Wa Ying,Wai-Fung Cheong,Yunlong Zhang,Xiaolu Su,Bo Xu,Jeffery J. Popma,Gregg W. Stone

DOI: https://doi.org/10.1016/j.jacc.2015.09.054

IF: 24

2015-01-01

Journal of the American College of Cardiology

Abstract:BACKGROUND The everolimus-eluting bioresorbable vascular scaffold (BVS) is designed to achieve results comparable to metallic drug-eluting stents at 1 year, with improved long-term outcomes. Whether the 1-year clinical and angiographic results of BVS are noninferior to current-generation drug-eluting stents has not been established.OBJECTIVES This study sought to evaluate the angiographic efficacy and clinical safety and effectiveness of BVS in a randomized trial designed to enable approval of the BVS in China.METHODS Eligible patients with 1 or 2 de novo native coronary artery lesions were randomized to BVS or cobalt-chromium everolimus-eluting stents (CoCr-EES) in a 1: 1 ratio stratified by diabetes and the number of lesions treated. Angiographic and clinical follow-up were planned at 1 year in all patients. The primary endpoint was angiographic in-segment late loss (LL), powered for noninferiority with a margin of 0.15 mm.RESULTS A total of 480 patients were randomized (241 BVS vs. 239 CoCr-EES) at 24 sites. Acute clinical device success (98.0% vs. 99.6%; p = 0.22) and procedural success (97.0% and 98.3%; p = 0.37) were comparable in BVS- and CoCr-EES-treated patients, respectively. The primary endpoint of in-segment LL at 1 year was 0.19 +/- 0.38 mm for BVS versus 0.13 +/- 0.38 mm for CoCr-EES; the 1-sided 97.5% upper confidence limit of the difference was 0.14 mm, achieving noninferiority of BVS compared with CoCr-EES (P-noninferiority = 0.01). BVS and CoCr-EES also had similar 1-year rates of target lesion failure (cardiac death, target vessel myocardial infarction, or ischemia-driven target lesion revascularization; 3.4% vs. 4.2%, respectively; p = 0.62) and definite/probable scaffold/stent thrombosis (0.4% vs. 0.0%, respectively; p = 1.00).CONCLUSIONS In the present multicenter randomized trial, BVS was noninferior to CoCr-EES for the primary endpoint of in-segment LL at 1 year. (A Clinical Evaluation of Absorb Bioresorbable Vascular Scaffold [Absorb BVS] System in Chinese Population-ABSORB CHINA Randomized Controlled Trial [RCT]; NCT01923740) (C) 2015 by the American College of Cardiology Foundation.
Magnetic Resonance (MR) Safety and Compatibility of a Novel Iron Bioresorbable Scaffold

Dong Bian,Li Qin,Wenjiao Lin,Danni Shen,Haiping Qi,Xiaoli Shi,Gui Zhang,Hongwei Liu,Han Yang,Jin Wang,Deyuan Zhang,Yufeng Zheng

DOI: https://doi.org/10.1016/j.bioactmat.2020.02.011

IF: 18.9

2020-01-01

Bioactive Materials

Abstract:Fully bioresorbable scaffolds have been designed to overcome the limitations of traditional drug-eluting stents (DESs), which permanently cage the native vessel wall and pose possible complications. The ultrathin-strut designed sirolimus-eluting iron bioresorbable coronary scaffold system (IBS) shows comparable mechanical properties to traditional DESs and exhibits an adaptive degradation profile during target vessel healing, which makes it a promising candidate in all-comers patient population. For implanted medical devices, magnetic resonance (MR) imaging properties, including MR safety and compatibility, should be evaluated before its clinical use, especially for devices with intrinsic ferromagnetism. In this study, MR safety and compatibility of the IBS scaffold were evaluated based on a series of well-designed in-vitro, ex-vivo and in-vivo experiments, considering possible risks, including scaffold movement, over-heating, image artifact, and possible vessel injury, under typical MR condition. Traditional ASTM standards for MR safety and compatibility evaluation of intravascular devices were referred, but not only limited to that. The unique time-relevant MR properties of bioresorbable scaffolds were also discussed. Possible forces imposed on the scaffold during MR scanning and MR image artifacts gradually decreased along with scaffold degradation/absorption. Rigorous experiments designed based on a scientifically based rationale revealed that the IBS scaffold is MR conditional, though not MR compatible before complete absorption. The methodology used in the present study can give insight into the MR evaluation of magnetic scaffolds (bioresorbable) or stents (permanent).
First‐in‐man Study Evaluating the Safety and Efficacy of a Second Generation Biodegradable Polymer Sirolimus‐eluting Stent in the Treatment of Patients with De Novo Coronary Lesions: Clinical, Angiographic, and OCT Outcomes of CREDIT‐1

Geng Wang,Zhongwei Sun,Quanmin Jin,Kai Xu,Yi Li,Xiaozeng Wang,Yingyan Ma,Haiwei Liu,Xin Zhao,Bin Wang,Jie Deng,Shaoyi Guan,Meiling Ge,Xiaoyan Wang,Bo Xu,Yaling Han

DOI: https://doi.org/10.1002/ccd.25862

IF: 2.3

2015-01-01

Catheterization and Cardiovascular Interventions

Abstract:ObjectiveTo evaluate the preliminary safety and efficacy of the EXCEL II stent system.BackgroundAlthough the first biodegradable polymer drug‐eluting stent (BP‐DES), EXCEL, was launched nearly a decade ago, in‐stent restenosis and stent thrombosis remain pertinent clinical problems in practice. A new cobalt‐chromium BP‐DES EXCEL II has been developed with the aim of improving stent safety and efficacy.MethodsForty‐five patients with single de novo native coronary lesions were enrolled and randomized to two groups in a 2:1 ratio, the 4‐month follow‐up group (n = 30) and the 12‐month follow‐up group (n = 15). All patients underwent percutaneous coronary intervention (PCI) with the EXCEL II stent system. Quantitative coronary angiography (QCA) and optical coherence tomography (OCT) were used to assess coronary vasculature at the designated 4‐ or 12‐month follow‐up. The primary outcome was major adverse cardiac events (MACE) at 30 days post‐PCI.ResultsNo MACE, thrombotic events, or target lesion failure was found in the 45 patients during the 12‐month follow‐up. There was no significant difference (P > 0.05) between the two groups in terms of in‐stent and in‐segment late lumen loss (LLL). No in‐stent and in‐segment restenosis was found in either group. At follow‐up, the ratio of >10% uncovered struts per lesion was 26.67% in the 4‐month group and 0% in the 12‐month group (P < 0.05). Neointimal coverage in the 12‐month group was significantly better than in the 4‐month group (98.58% vs. 93.51%, P < 0.01).ConclusionsThis first‐in‐man study demonstrates promising feasibility, safety, and efficacy of EXCEL II stents. These stents were found to have rapid endothelialization and low LLL rates at 4 and 12 months after implantation. © 2015 Wiley Periodicals, Inc.
Nine-month Angiographic and Two-year Clinical Follow-up of Novel Biodegradable-polymer Arsenic Trioxide-eluting Stent Versus Durable-polymer Sirolimus-eluting Stent for Coronary Artery Disease

Li Shen,Wei Yang,Jia-Sheng Yin,Xue-Bo Liu,Yi-Zhe Wu,Ai-Jun Sun,Ju-Ying Qian,Jun-Bo Ge

DOI: https://doi.org/10.4103/0366-6999.152490

2015-01-01

Abstract:BACKGROUND:Despite great reduction of in-stent restenosis, first-generation drug-eluting stents (DESs) have increased the risk of late stent thrombosis due to delayed endothelialization. Arsenic trioxide, a natural substance that could inhibit cell proliferation and induce cell apoptosis, seems to be a promising surrogate of sirolimus to improve DES performance. This randomized controlled trial was to evaluate the efficacy and safety of a novel arsenic trioxide-eluting stent (AES), compared with traditional sirolimus-eluting stent (SES).METHODS:Patients with symptoms of angina pectoris were enrolled and randomized to AES or SES group. The primary endpoint was target vessel failure (TVF), and the second endpoint includes rates of all-cause death, cardiac death or myocardial infarction, target lesion revascularization (TLR) by telephone visit and late luminal loss (LLL) at 9-month by angiographic follow-up.RESULTS:From July 2007 to 2009, 212 patients were enrolled and randomized 1:1 to receive either AES or SES. At 2 years of follow-up, TVF rate was similar between AES and SES group (6.67% vs. 5.83%, P = 0.980). Frequency of all-cause death was significantly lower in AES group (0 vs. 4.85%, P = 0.028). There was no significant difference between AES and SES in frequency of TLR and in-stent restenosis, but greater in-stent LLL was observed for AES group (0.29 ± 0.52 mm vs. 0.10 ± 0.25 mm, P = 0.008).CONCLUSIONS:After 2 years of follow-up, AES demonstrated comparable efficacy and safety to SES for the treatment of de novo coronary artery lesions.
Interstitial granulomatous dermatitis with arthritis presenting with the rope sign

F. Worsnop,L. Ostlere

DOI: https://doi.org/10.1111/ced.12052

2013-07-01

Abstract:We report a case of interstitial granulomatous dermatitis with arthritis presenting with rope-like lesions on the trunk and arms. A 36-year-old man presented with a 1-year history of rope-like lesions over both flanks, extending upwards to his arms. The patient reported that 1 week before the skin changes occurred, he had developed a sudden and severe pain in his flanks after lifting a heavy box. He had a 16-year history of bilateral knee pain, and a 3-month history of morning stiffness with pain in the fingers, wrists, elbows, shoulders and ankles, which had resulted in him being unable to work. On physical examination, palpable dermal linear cord-like lesions with overlying erythema were seen on both sides of the patient’s trunk and extending upwards along the proximal surface of his arms. These lesions measured > 400 mm in length and 8–10 mm in width (Fig. 1a). When the patient moved his torso or raised his arms, he experienced a sensation of pain and tightness overlying the lesions (Fig. 1b). On histological examination of a skin biopsy, a dense diffuse interstitial histiocytic infiltrate, with neutrophils, lymphocytes, plasma cells and eosinophils, was seen in the section (Fig. 2). Laboratory investigations showed an increase in inflammatory markers: erythrocyte sedimentation rate was 11 mm/h (normal range 0–7 mm/h) and C-reactive protein was 17 mg (normal range < 6 mg/h). Tests were negative for antinuclear antibody, positive for rheumatoid factor (374 U/mL; normal range < 40 U/mL) and strongly positive for anticyclic citrullinated peptide (600 IU/mL; < 4 IU/mL). Given the signs and symptoms of arthritis and the strongly positive serology results, the patient was diagnosed as having rheumatoid arthritis (RA). The characteristic rope-like lesions, histological findings and serological results were consistent with a final diagnosis of interstitial granulomatous dermatitis with arthritis (IGDA). IGDA was first recognized as a distinct condition in 1995 by Ackerman et al. It is an unusual condition with a variable clinical presentation and characteristic histology. The ‘rope sign’, as found in our case, with linear palpable cords, is the most specific but least commonly seen cutaneous appearance. Other presentations include erythematous or skin-coloured plaques, papules and nodules. The ‘rope sign’ was initially thought to be pathognomonic; however, Mondor disease (MD) can present similarly and must be included in the differential diagnosis. MD is characterized by a superficial thrombophlebitis, and can be easily Correspondence: Dr Fiona S. Worsnop, Department of Dermatology, St Georges Hospital, Blackshaw Road, London, SW17 0QT, UK E-mail: fionaworsnop@nhs.net
A Randomized Trial Comparing the NeoVas Sirolimus-Eluting Bioresorbable Scaffold and Metallic Everolimus-Eluting Stents.

Yaling Han,Bo Xu,Guosheng Fu,Xiaozeng Wang,Kai Xu,Chongying Jin,Ling Tao,Lang Li,Yuqing Hou,Xi Su,Quan Fang,Lianglong Chen,Huiliang Liu,Bin Wang,Zuyi Yuan,Chuanyu Gao,Shenghua Zhou,Zhongwei Sun,Yanyan Zhao,Changdong Guan,Gregg W. Stone

DOI: https://doi.org/10.1016/j.jcin.2017.09.037

2018-01-01

Abstract:OBJECTIVES The authors sought to evaluate the safety and effectiveness of the NeoVas bioresorbable scaffold (BRS) compared with metallic drug-eluting stents. BACKGROUND BRS have the potential to improve very late outcomes compared with metallic drug-eluting stents, but some BRS have been associated with increased rates of device thrombosis before complete bioresorption. NeoVas is a new poly-L-lactic acid BRS that elutes sirolimus from a poly-D, L-lactide coating. METHODS Eligible patients with a single de novo native coronary artery lesion with a reference vessel diameter 2.5 to 3.75 mm and a lesion length <= 20 mm were randomized 1: 1 to NeoVas BRS versus cobalt-chromium everolimus-eluting stents (CoCr-EES). Angiographic follow-up was performed in all patients at 1 year. The primary endpoint was angio-graphic in-segment late loss (LL), and the major secondary endpoint was the rate of angina. Baseline and follow-up optical coherence tomography and fractional flow reserve were performed in a pre-specified subgroup of patients. RESULTS The authors randomized 560 patients at 32 centers to treatment with NeoVas (n = 278) versus CoCr-EES (n = 282). One-year in-segment LL with NeoVas and CoCr-EES were 0.14 +/- 0.36 mm versus 0.11 +/- 0.34 mm (difference 0.03 mm; upper 1-sided 97.5% confidence interval 0.09 mm; p(noninferiority) < 0.0001; p(superiority) = 0.36). Clinical outcomes at 1 year were similar in the 2 groups, as were the rates of recurrent angina (27.9% vs. 32.1%; p = 0.26). Optical coherence tomography at 1 year demonstrated a higher proportion of covered struts (98.7% vs. 96.2%; p < 0.001), less strut malapposition (0% vs. 0.6%; p < 0.001), and a smaller minimal lumen area (4.71 +/- 1.64 vs. 6.00 +/- 2.15 mm(2); p < 0.001) with NeoVas compared with CoCr-EES respectively, with nonsignificant differences in fractional flow reserve (0.89 +/- 0.08 vs. 0.91 +/- 0.06; p = 0.07). CONCLUSIONS The NeoVas BRS was noninferior to CoCr-EES for the primary endpoint of 1-year angiographic in-segment LL, and resulted in comparable 1-year clinical outcomes, including recurrent angina. (C) 2018 Published by Elsevier on behalf of the American College of Cardiology Foundation.
A Prospective, Randomized Trial of Bioresorbable Polymer Drug-Eluting Stents Versus Fully Bioresorbable Scaffolds in Patients Undergoing Coronary Stenting

Jens Wiebe,Robert A. Byrne,Christian Bradaric,Constantin Kuna,Thorsten Kessler,Mathieu Pfleiderer,Sebastian Kufner,Erion Xhepa,Petra Hoppmann,Michael Joner,Heribert Schunkert,Karl-Ludwig Laugwitz,Adnan Kastrati,Salvatore Cassese

DOI: https://doi.org/10.3390/jcm13195949

IF: 3.9

2024-10-08

Journal of Clinical Medicine

Abstract:Background: The performance of an everolimus-eluting bioresorbable scaffold (BRS) was inferior to an everolimus-eluting metallic drug-eluting stent (DES) with permanent polymer, mainly due the mechanical features of BRS technology. The performance of BRS as compared to metallic DES with bioresorbable polymers remains unstudied. Methods: This prospective, randomized, multicenter, clinical trial enrolled patients who underwent coronary stenting for de novo coronary lesions. Patients were randomly assigned to bioresorbable polymer everolimus-eluting stents (BP-EES) or everolimus-eluting BRS. The primary endpoint was percentage diameter stenosis (in-device) at 6- to 8-month angiographic surveillance. The main secondary endpoint was the device-oriented composite endpoint (DOCE) of cardiac death/target vessel-myocardial infarction/target lesion revascularization assessed after 12 months and 5 years. Results: The trial was prematurely terminated after the enrollment of 117 of 230 patients (BP-EES, n = 60; BRS, n = 57) due to safety issues associated with BRS technology. The primary endpoint of in-device diameter stenosis at angiographic surveillance was 12.5 ± 7.7% with BP-EES versus 19.3 ± 16.5% with BRS (p = 0.01). The DOCE occurred in 5.0% in the BP-EES group versus 12.3% of patients in the BRS group (hazard ratio [HR] 2.48, 95% confidence interval [CI] 0.64–9.58, p = 0.19) after 12 months and in 11.7% in the BP-EES group versus 26.4% of patients in the BRS group (HR 2.38, 95% CI 0.97–5.84, p = 0.06) after 5 years. Conclusions: BP-EES showed superior mid-term angiographic performance compared with BRS. Clinical event rates did not differ significantly between the groups up to 5 years of follow-up. These results should be interpreted with caution in view of the premature discontinuation of the study.

medicine, general & internal

Regional enteritis involving the duodenum: report of case.

Biolimus-coated Versus Paclitaxel-Coated Balloons for Coronary In-Stent Restenosis (BIO ASCEND ISR): a Randomised, Non-Inferiority Trial.

A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial

Thinner-Strut Sirolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents in Patients with Coronary Artery Disease: FUTURE-II Trial

A randomized comparison of healing response of the BuMA Supreme stent and Xience stent at one- and two-month follow-up: PIONEER-II OCT randomized controlled trial.

Long-Term Efficacy, Safety and Biocompatibility of a Novel Sirolimus Eluting Iron Bioresorbable Scaffold in a Porcine Model

GW29-e2015 Primary Endpoint Outcomes of A Prospective, Single-Blinded, Multi-Center, Randomized, Controlled, Clinical Trial on the Efficacy and Safety of Sirolimus-Eluting Stent (mistent® System) Compared to TIVOLI in the Treatment of Patients with Coronary Heart Disease

In vivo degradation and endothelialization of an iron bioresorbable scaffold

Design and Rationale of Targeted Therapy With a Sirolimus-Eluting, Biodegradable Polymer Coronary Stent in Chronic Total Occlusions (TARGET CTO): A Multicenter, Open-Label, Randomized Noninferiority Trial.

Twelve-month Angiographic and Clinical Outcomes of the XINSORB Bioresorbable Sirolimus-Eluting Scaffold and a Metallic Stent in Patients with Coronary Artery Disease

Mid-to-long term clinical outcomes with everolimus-eluting bioresorbable vascular scaffold versus everolimus-eluting metallic stent in coronary artery diseases: a meta-analysis of 7321 patients

Three-year Clinical Outcomes of a Sirolimus-Eluting Bioresorbable Scaffold (XINSORB) and a Metallic Stent to Treat Coronary Artery Stenosis.

Sirolimus-eluting Cobalt Alloyed Stents in Treating Patients with Coronary Artery Disease: Six-Month Angiographic and One-Year Clinical Follow-Up Result A Prospective, Historically Controlled, Multi-Center Clinical Study

Regarding ‘efficacy and safety of a new surgical method to treat malignant glaucoma in pseudophakia’

Bioresorbable Vascular Scaffolds Versus Metallic Stents in Patients with Coronary Artery Disease: ABSORB China Trial.

Magnetic Resonance (MR) Safety and Compatibility of a Novel Iron Bioresorbable Scaffold

First‐in‐man Study Evaluating the Safety and Efficacy of a Second Generation Biodegradable Polymer Sirolimus‐eluting Stent in the Treatment of Patients with De Novo Coronary Lesions: Clinical, Angiographic, and OCT Outcomes of CREDIT‐1

Nine-month Angiographic and Two-year Clinical Follow-up of Novel Biodegradable-polymer Arsenic Trioxide-eluting Stent Versus Durable-polymer Sirolimus-eluting Stent for Coronary Artery Disease

Interstitial granulomatous dermatitis with arthritis presenting with the rope sign

A Randomized Trial Comparing the NeoVas Sirolimus-Eluting Bioresorbable Scaffold and Metallic Everolimus-Eluting Stents.

A Prospective, Randomized Trial of Bioresorbable Polymer Drug-Eluting Stents Versus Fully Bioresorbable Scaffolds in Patients Undergoing Coronary Stenting